The QualityStocks Daily Thursday, September 24th, 2020

Today's Top 3 Investment Newsletters

TradersPro (SUNW) +238.79%

MarketClub Analysis (PECK) +131.67%

NetworkNewsWire (SHRG) +68.48%

The QualityStocks Daily Stock List

Alternet Systems, Inc. (ALYI)

WallStreetWindow, Financial News Media, Trade Ideas, OTC Markets, OTC Dynamics, Simply Wall St, MicroCapDaily, Business Insider, Newsfilecorp, Fintel, Investing.com, Market Screener, Seeking Alpha, PR Newswire, MarketWatch, GuruFocus, Nasdaq, Wallet Investor, TradingView, Morningstar, Dividend Investor, Macroaxis, Barchart, News Break, Stockhouse, GlobeNewswire, Proactive Investors, and InvestorsHub reported earlier on Alternet Systems, Inc. (ALYI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alternet Systems, Inc. focuses on sustainable energy storage applications. The Company has developed a comprehensive, long-term electric mobility business strategy centered on quickly expanding into the market in Sub-Saharan Africa. Its strategy starts with the production of its proprietary ReVolt Electric Motorcycle. The design of it is for a rugged environment and to support the multi passenger Ride-Share industry in Africa. Alternet Systems lists on the OTC Markets.

The Company has changed from managing the development of a portfolio of patented lithium technologies. It maintains initiatives in alternative energy storage research and development (R&D), and in energy storage needs specific to military applications.

The ReVolt Electric Motorcycle is Alternet Systems’ first electric vehicle. Additional electric vehicles are in the works. The ReVolt Electric Motorcycle has undergone development through numerous pilot phases. An industrial engineering firm is now designing the manufacturing capacity to mass produce the ReVolt Electric Motorcycle.

Regarding Energy Storage, Alternet Systems has re-focused its strategy on finding unique solutions to energy storage shortages. The Company states that those solutions do not necessarily need to come from Lithium-Ion based technology. Alternet Systems is exploring an array of energy storage R&D initiatives. Much of the leading development is taking place at universities. The Company is looking to structure partnerships with R&D organizations to commercialize their technology through building that technology into specific applications.

This week, Alternet Systems confirmed it entered into a Letter of Intent (LOI) agreement with a new potential customer for ReVolt Electric Motorcycles, which could expand Alternet's $300 million potential revenue outlook to $500 million. The Company has already entered into an initial $20 million electric motorcycle order and an additional LOI agreement for a $30 million contract. Both the $20 million and $30 million commitments are in Kenya.

The new order under LOI, and expected to result in a confirmed order by the end of September, is in Ethiopia. Alternet Systems has initiated its electric mobility emphasis first in Sub-Saharan Africa where per capita transportation infrastructure is considerably under resourced. The Company says that prevailing low per capital transportation infrastructure is ideal for technology leapfrog opportunities.

Alternet Systems says it is approaching the electric vehicle market with a comprehensive and long-term view. The Company is working to build an electric mobility ecosystem that connects ever developing technology with an environmentally sensitive transportation solution driven by a host of consumer expectations that are ever changing in reaction to new technologies and competitive offerings.

Alternet Systems, Inc. (ALYI), closed Thursday's trading session at $0.0115, off by 14.8148%, on 78,119,112 volume with 1,330 trades. The average volume for the last 3 months is 89,966,216 and the stock's 52-week low/high is $0.050700001/$0.300999999.

Curis, Inc. (CRIS)

Zacks, Business Insider, Simply Wall St, StreetWise Reports, BioPharmaJournal, AI Stock Finder, BioPharmCatalyst, BioSpace, Market Chameleon, Newsheater, Investing.com, PR Newswire, InvestorsHub, Proactive Investors, Equity Clock, Dividend Investor, Morningstar, Finbox, Stocknews, Investors Observer, YCharts, DBT News, and Equities.com reported beforehand on Curis, Inc. (CRIS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

A biotechnology enterprise, Curis, Inc. concentrates on the development of inventive therapeutics for the treatment of cancer. The Company is working to develop unique and differentiated therapeutics that improve the lives of cancer patients. Its corporate mission and strategy is on developing the new generation of targeted cancer drugs. Curis has its head office in Lexington, Massachusetts. The Company lists on the NasdaqGS.

Curis works to develop novel, first-in-class, cancer therapeutics that it believes have major potential in areas of unmet patient need. In 2015, it entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints. These include the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948.

Currently, CA-4948 is undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993. This is a monoclonal anti-VISTA antibody. Furthermore, Curis is party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

In August, Curis reported its financial results for Q2 ended June 30, 2020. For Q2 2020, the Company reported a Net Loss of $6.7 million, or $0.17 per share on both a basic and diluted basis, versus a Net Loss of $7.2 million, or $0.22 per share on both a basic and diluted basis, for the same period in 2019. Curis reported a Net Loss of $16.4 million, or $0.44 per share on both a basic and diluted basis, for the six months ended June 30, 2020, versus a Net Loss of $17.1 million, or $0.52 per share on both a basic and diluted basis, for the same period in 2019.

Revenues for Q2 2020 were $2.4 million, versus $2.1 million for the same period in 2019. Revenues for the six months ended June 30, 2020 were $5.1 million, versus $3.9 million for the same period in 2019. Revenues for both periods consist of chiefly Royalty Revenues recorded on Genentech and Roche's Net Sales of Erivedge®.

Curis, Inc. (CRIS), closed Thursday's trading session at $1.04, off by 3.7037%, on 354,717 volume with 935 trades. The average volume for the last 3 months is 933,729 and the stock's 52-week low/high is $0.022454999/$20.3600006.

LiveXLive Media, Inc. (LIVX)

Stocktwits, Webull, The Stock Market Watch, Market Chameleon, Investing.com, Stockhouse, Morningstar, Barchart, Market Screener, YCharts, Investors Observer, TipRanks, last10k, MarketBeat, Finviz, Seeking Alpha, Zacks, Simply Wall St, InvestorsHub, ETF.com, MacroTrends, Nasdaq, Stockopedia, Business Insider, Dividend.com, and MarketWatch reported earlier on LiveXLive Media, Inc. (LIVX), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

LiveXLive Media, Inc. is an international platform for livestream and on-demand audio, video, and podcast content in music, comedy, and pop culture. The Company has streamed more than 1200 artists since January of this year. It has become a go-to partner for the globe’s leading artists and celebrity voices and also music festivals concerts. These include Rock in Rio, EDC Las Vegas, and also many others. LiveXLive Media has its corporate headquarters in Beverly Hills, California.

In April of this year, LiveXLive produced its first 48-hour music festival called "Music Lives" with great success as the Company earned more than 50 million views and greater than 5 billion views for #musiclives on TikTok on 100-plus performances. LiveXLive's library of worldwide events, video-audio podcasts, and original shows are also available on Amazon, Apple TV, Roku, and Samsung TVs in addition to its own app, destination site, and social channels. Its wholly-owned subsidiary, PodcastOne, generates greater than 2.1 billion downloads yearly across over 300 podcasts.

This week, LiveXLive Media announced its mobile expansion in Latin America through a new exclusive video distribution deal with ICARO Media Group. ICARO is a provider of the most advanced AI (Artificial Intelligence), digital media platform, and content aggregation platform in partnership with worldwide telecoms and media companies who control the immediate access to their subscribers. As part of this expansion, LiveXLive will make its video library available to millions of customers in Latin America by way of ICARO Media Group's technology.

LiveXLive Media will exclusively stream the 2020 iHeartCountry Festival Presented by Capital One, originally scheduled for May 2, 2020 at the Frank Erwin Center in Austin, Texas on October 23, 2020. The seventh annual event, recorded live on one stage in Nashville, features performances from Dierks Bentley, Lady A, Sam Hunt, Kane Brown, Kelsea Ballerini, Dustin Lynch, Jon Pardi, Riley Green, Special Performances by Morgan Evans and Gabby Barrett and a Guest Appearance by Bobby Bones.

LiveXLive Media, Inc. (LIVX), closed Thursday's trading session at $2.64, up 1.5385%, on 297,088 volume with 2,515 trades. The average volume for the last 3 months is 971,287 and the stock's 52-week low/high is $1.00999999/$3.32999992.

Macarthur Minerals Limited (MMSDF)

Resource World, The Online Investor, Northern Miner, Junior Mining Network, The Prospector News, Mining Stock Education, Nasdaq, InvestorsHub, GuruFocus, Market Screener, PR Newswire, Simply Wall St, Annual Reports, GlobeNewswire, Investing News, Stockhouse, Fintel, TMXmoney, MarketWatch, Global Banking and Finance, Barchart, OTC Markets, 24hgold, Seeking Alpha, Wallet Investor, Stockwatch, and Proactive Investors reported earlier on Macarthur Minerals Limited (MMSDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Macarthur Minerals Limited is an iron ore development, gold, and lithium exploration enterprise. The Company is centered on bringing to production its 100 percent owned Western Australia iron ore projects. The Company previously went by the name Macarthur Diamonds Limited. It changed its corporate name to Macarthur Minerals Limited in July of 2005. The Company has its head office in Toowong, QLD 4066, Australia. Macarthur Minerals’ shares trade on the OTC Markets Group’s OTCQB.

The Lake Giles Iron Project mineral resources include the Ularring hematite resource (approved for development) consisting of Indicated resources of 54.5 million tonnes at 47.2 percent Fe and Inferred resources of 26 million tonnes at 45.4 percent Fe; and the Lake Giles magnetite resource of 53.9 million tonnes (Measured), 218.7 million tonnes (Indicated) and 997 million tonnes (Inferred).

Macarthur Minerals has prominent (an approximately 721 square kilometer tenement area) gold, lithium, and copper exploration interests in the Pilbara region of Western Australia. Furthermore, the Company has lithium brine claims in the emerging Railroad Valley area in the State of Nevada.

The Company has secured a binding Life-of-Mine Off-Take Agreement with Glencore International A.G. and is focused on commercializing its iron ore projects utilizing mining, processing and logistics infrastructure in the region and is progressing towards completing a bankable feasibility study.

Pertaining to its Gold Strategy, Macarthur Minerals states that it has created a very valuable portfolio of conglomerate/greenstone gold tenements in the Pilbara Region of Western Australia. This portfolio comprises 11 granted Exploration Licenses. The Company’s 100 percent owned Hillside Gold Project will be the priority exploration emphasis as these tenements have had existing historic small-scale gold mining activity. More than 700 oz of gold nuggets have been found by prospectors on these tenements. The Exploration Licenses were progressively granted during November/December 2017.

Regarding Nevada Lithium, Macarthur Minerals, via its wholly-owned U.S. subsidiary, Macarthur Lithium Nevada Limited, staked 210 new unpatented placer mining claims at its new Reynolds Springs Lithium Brine Project (Reynolds Springs Project) in the Railroad Valley, Nevada. These claims are positioned near the town of Currant, in Nye County, Nevada. The Reynolds Springs Project is situated roughly 180 miles (300 km) North of Las Vegas, Nevada, and 330 miles (531 km) South East of Tesla’s Gigafactory.

Macarthur Minerals Limited (MMSDF), closed Thursday's trading session at $0.2994, off by 14.4082%, on 4,592 volume with 7 trades. The average volume for the last 3 months is 75,655 and the stock's 52-week low/high is $3.10500001/$11.9300003.

Odyssey Group International, Inc. (ODYY)

Stock Gumshoe, Barchart, News Break, OTC Markets, PennyStocks.News, GuruFocus, last10k, TipRanks, Market Wire News, Penny Stock Hub, Dividend Investor, Stockwatch, Simply Wall St, CSI Market, docoh, Market Screener, StockInvest.us, PitchBook, InvestorsHub, Baystreet.ca, Seeking Alpha, Ask Finny, CRWE World, and Wallet Investor reported earlier on Odyssey Group International, Inc. (ODYY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Odyssey Group International, Inc. is a technology and asset acquisition company focused on developing unique, life-saving medical products. Its mission is to create, acquire, as well as accumulate distinct assets, intellectual properties (IPs), and exceptional technologies that provide meaningful medical solutions. Odyssey was formed as a publicly held holding company with an emphasis on the development and acquisition of medical devices and health related technologies.

Odyssey Group is set to capitalize on the multi-billion dollar cardiology market. Founded in 2014, Odyssey Group International has its corporate headquarters in Irvine, California. The Company lists on the OTC Markets’ OTCQB.

Odyssey Group focuses on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a significant market opportunity, and provide strong returns to its shareholders and partners. Its initial product technology is the CardioMap® heart monitoring and screening device.

The CardioMap® heart monitoring and screening device provides early, non-invasive testing of heart disease. It features a highly portable design and web-based analysis. CardioMap® opens up possibilities for remote and home screening.

Odyssey Group International has partnered with Prevacus, Inc. Prevacus has been developing a nasal spray to treat concussions. This partnership is to develop Prevacus' neuroprotectant compounds for brain injuries and other leukodystrophies. Prevacus is a biopharmaceutical company centered on developing treatments for concussion (mild traumatic brain injury (mTBI)) and Niemann Pick Type C. In addition, Odyssey has acquired Second Chance, who has developed a personal anti-choking device to save lives.

Recently, Odyssey Group International announced that on August 14, 2020, it entered into a common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Upon entering into the Agreements, LPC made an initial investment of $250,000.

Odyssey Group International Chairman and Chief Executive Officer, Mr. Michael Redmond, said, "We are extremely happy to partner with Lincoln Park Capital. We are confident that the existing capital structure will support our short-term operational cash flow requirements while providing the flexibility to achieve our long-term growth targets. We look forward to furthering the development of both our Save A Life choking rescue device and CardioMap device with the ultimate goal of an FDA submission on each."

Odyssey Group International, Inc. (ODYY), closed Thursday's trading session at $0.2802, off by 3.3793%, on 20,702 volume with 21 trades. The average volume for the last 3 months is 94,517 and the stock's 52-week low/high is $0.379999995/$1.95000004.

Salarius Pharmaceuticals, Inc. (SLRX)

NetworkNewsWire, Stocklight, BioPharmCatalyst, Stocktwits, MarketWatch, Biz Journals, Nasdaq, ChartMill, Invest Chronicle, YCharts, last10k, TipRanks, Street Insider, ADVFN, Proactive Investors, Market Chameleon, GuruFocus, Barchart, Stockhouse, Morningstar, Business Wire, Stockopedia, ETF.com, Investors Observer, Seeking Alpha, MarketBeat, Simply Wall St, GlobeNewswire, and Dwinnex reported earlier on Salarius Pharmaceuticals, Inc. (SLRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression. It is developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors.

The Company’s lead compound is Seclidemstat. Salarius states that Seclidemstat represents a potential paradigm shift in the treatment of cancer. It is initially targeting Ewing sarcoma, a devastating pediatric, adolescent, and young adult bone cancer where no targeted therapies are presently available. The U.S. Food and Drug Administration (FDA) has granted Seclidemstat Fast Track Designation and also Orphan and Rare Pediatric Disease Designations, in recognition of the high unmet medical need facing Ewing sarcoma patients. Salarius Pharmaceuticals is headquartered in Houston, Texas and lists on the NasdaqGS.

Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program. The Company is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).

The Company’s technology targets the epigenetic causes of cancer. This is the study of the regulatory system that controls how genes are turned “on” or “off.” In certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off.” In some cases this leads to cancer progression.

Drugs that can safely modify the activity of these epigenetic regulators may correct the gene changes that are driving disease. Furthermore, Salarius Pharmaceuticals’ technology may apply to hormonal cancers. These include prostate, breast, ovarian cancer, and maybe other conditions such as leukemia.

Salarius programs include Epigenetics and LSD1. Lysine specific histone demethylase 1 (LSD1, also called KDM1A) is an epigenetic “eraser”. The Company’s lead molecule, Seclidemstat, is a reversible LSD1 inhibitor. Seclidemstat inhibits LSD1's demethylation and scaffolding properties. This represents a feasible therapeutic option for patients who need it the most.

Recent business and corporate highlights for Salarius Pharmaceuticals include the Ewing sarcoma clinical trial expanding to include Ewing-related sarcomas supported by clinical observations. This includes observation of seclidemstat activity in a patient with refractory Ewing sarcoma. The Ewing sarcoma Phase 1/2 clinical trial and advanced solid tumor (AST) Phase 1/2 clinical trial continue to enroll patients during COVID-19.

Moreover, Salarius Pharmaceuticals presented seclidemstat data to the Pediatric Oncology Subcommittee of the FDA’s Oncologic Drugs Advisory Committee (ODAC). The European Patent Office (EPO) issued Patent EP2744330 for seclidemstat.

Salarius Pharmaceuticals, Inc. (SLRX), closed Thursday's trading session at $0.7699, off by 4.2413%, on 101,271 volume with 323 trades. The average volume for the last 3 months is 255,642 and the stock's 52-week low/high is $1.71000003/$9.60000038.

WeedMD, Inc. (WDDMF)

NetworkNewsWire, Morningstar, Daily Marijuana Observer, Greenshoe Media Group, Financial Insiders, Micro Small Cap, Midas Letter, OTC.Watch, Street Insider, Fortune420, The Cannabis Investor, Micro Small Cap, Wallmine, Profit Confidential, Investor Ideas, Stockwatch, Stock Day Media, GuruFocus, OTC Markets, NIC Investors, MG Retailer, Marijuana Stock Review, CannabisMarketCap, New Cannabis Ventures, Financial Buzz, Technical420, and Pot Stock News reported previously on WeedMD, Inc. (WDDMF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

WeedMD, Inc. is a federally-licensed producer and distributor of medical-grade cannabis. The Company is the publicly-traded parent company of WeedMD RX, Inc. and Starseed Medicinal, Inc., federally-licensed producers of cannabis products for the medical and adult-use markets. WeedMD has a multi-channeled distribution strategy. This includes selling directly to medical patients, strategic relationships across the seniors’ market, and supply agreements with Shoppers Drug Mart and six provincial distribution agencies where adult-use brands Color Cannabis and Saturday sell. WeedMD is headquartered in Aylmer, Ontario. The Company’s shares trade on the OTC Markets Group’s OTCQX.

WeedMD owns and operates a 158-acre state-of-the-art greenhouse, outdoor, and processing facility in Strathroy, Ontario and also CX Industries, Inc., a wholly-owned subsidiary that specializes in cannabis extraction from the Company’s fully-licensed 26,000 sq. ft. Aylmer, Ontario processing facility. With the addition of the Starseed Medicinal, WeedMD has expanded its multi-channeled distribution strategy. Starseed is a medical-centric operator headquartered in Bowmanville, Ontario. Starseed’s industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, along with other employers and union groups complements WeedMD’s direct sales to medical patients.

WeedMD has its Color™ Cannabis. Color Cannabis was developed specifically for a varied adult-use market that reflects the range in tastes and preferences of modern cannabis consumers. Color Cannabis products include a variety of strains, in numerous formats, developed with first-rate quality cannabis. Color Cannabis is a premier brand exclusively available to distributors and select retailers throughout Canada.

This week, WeedMD announced that it secured an amendment to its Health Canada licences permitting it to produce, package, sell, and distribute all cannabis formats directly from its 610,000-square-foot flagship cultivation and processing site in Strathroy, Ontario. Its hybrid-greenhouse in Strathroy is now operating at full capacity under a 210,000 square foot canopy alongside additional drying and processing space. WeedMD’s 27-acre, low-cost, outdoor grow, now in its second year of operation, is situated on-site along with a 50,000 square foot stand-alone, licensed processing facility dedicated for outdoor cannabis processing.

Moreover, this week, WeedMD announced it has merged its online medical product marketplaces under one platform and expanded its product offerings. The simplified Starseed Medicinal, Inc. sales platform provides WeedMD’s patients with full access to WeedMD-produced dried flower, oil concentrates, softgel capsules, and Aurum vaporization (vape) products and services, including same-day delivery.

WeedMD is the cultivator and producer. It will complete its full patient migration to its wholly-owned streamlined Starseed Medicinal online marketplace by early October 2020. Once merged, all patients will have access to WeedMD’s product offerings. This includes access to Mary’s Medicinals topicals gels and creams scheduled to roll out later in 2020.

WeedMD, Inc. (WDDMF), closed Thursday's trading session at $0.2241, off by 10.36%, on 75,467 volume with 74 trades. The average volume for the last 3 months is 96,074 and the stock's 52-week low/high is $1.13999998/$14.25.

H/Cell Energy Corporation (HCCC)

Market Wire News, Stock Analysis, Financial Buzz, Dividend Investor, All Penny Stocks, OTC Markets, Uptick Newswire, YCharts, MarketBeat, Street Insider, FairlyValued, 4-Traders, Morningstar, FX Empire, Equities, Stockwatch, Stockopedia, Market Screener, Business Wire, Simply Wall St, EIN Presswire, Stockhouse, last10k, and Wallet Investor reported earlier on H/Cell Energy Corporation (HCCC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

H/Cell Energy Corporation designs and implements clean energy solutions featuring hydrogen and fuel cell technology. The Company is an integrator that centers on the design and implementation of clean energy solutions. This includes solar, battery, fuel cell, and hydrogen generation systems. Through its subsidiaries, H/Cell also provides environmental systems and security systems integration. H/Cell Energy is based in Dallas, Texas. Established in 2015, the Company lists on the OTC Markets’ OTCQB.

H/Cell Energy serves the residential, commercial, as well as government sectors. The Company has developed and implemented a hydrogen energy system used to totally power a residence or commercial property with clean energy. This is so it can run independent of the utility grid and also provide energy to the utility grid for monetary credits. The unique system uses renewable energy as its source for hydrogen production.

The design of the HC-1 system is to provide clean energy for a better environment. The system eliminates the electric bill and dependence on fossil fuels. Moreover, the system enables one to benefit with tax and energy credits while helping make the environment safe for future generations. The HC-1 system is completely scalable. Upon installation, the HC-1 system operates as a self-sustaining energy system providing electricity and/or hydrogen fuel for transportation.

The design of each HC-1 system is to accommodate the electrical loads for an end user. The system can be configured to meet any kilowatt hour (kWh) demands. The installation includes solar panels, a hydrogen generator, a fuel cell, and a tank that would be located exterior to the property with the battery system located interior to the property.

This past May, H/Cell Energy announced financial results for its Q1 ended March 31, 2020. For the three months ended March 31, 2020, the Company produced Revenue of $1,667,947 and a Net Loss of $261,761. This includes $68,701 of non-cash charges that do not affect the cash flow performance or working capital of H/Cell Energy. This amounts to a $(0.04) per share Loss.

In comparison, for Q1 ended March 31, 2019, the Company generated Revenue of $1,704,273 and a Net Loss of $143,638. This included $111,153 of non-cash charges. This amounted to a $(0.02) per share Loss.

H/Cell Energy Corporation (HCCC), closed Thursday's trading session at $0.28, up 33.3333%, on 425 volume with 2 trades. The average volume for the last 3 months is 3,679 and the stock's 52-week low/high is $0.109999999/$0.844799995.

Concrete Leveling Systems, Inc. (CLEV)

Penny Stock Base, Awesome Penny Stocks, GuruFocus, Barchart, Business Insider, Dividend.com, Capital Cube, Stockopedia, Wallet Investor, Dividend Investor, 4-Traders, last10k, Stockhouse, Street Insider, Current Charts, InvestorsHub, Seeking Alpha, GlobeNewswire, Stockwatch, and YCharts reported previously on Concrete Leveling Systems, Inc. (CLEV), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Concrete Leveling Systems, Inc. manufactures and sells specialized equipment for end users in the concrete leveling industry. It provides the equipment, knowledge, and technical training to solve concrete settlement inquires. The Company provides a simple solution that is efficient and environmentally friendly at raising and re-aligning sunken concrete slabs to their original position. Incorporated in 2007, Concrete Leveling Systems has its head office in Canton, Ohio.

Concrete Leveling Systems’ Pro X-8 concrete leveling service unit package offers a low cost, high profit alternative to traditional removal and replacement options. Utilizing a series of 1 inch diameter holes the Pro X-8 stores, dispatches, mixes, and pumps a water based slurry, which upon injection through the pre-drilled holes, raises and re-aligns concrete slabs back to their original position. As the slabs are being raised, the slurry continues to fill and must attain compression before the concrete slab is raised. It is this “compression” of the pumping slurry that allows for the repaired area to be a permanent repair.

The Pro X-8 service unit package features a 16 hp Hydrapak, hopper and sub-framing that are of stainless steel construction. All machined steel parts are blasted and powder coated for optimal corrosion protection. The design of the Pro X-8 service unit package is for user-friendliness, maintenance, and cleaning.

Concrete Leveling Systems previously advised and updated its Shareholders in 2019 regarding the present direction and progress of the Company. Jericho Associates, Inc. is a Nevada corporation formed as a special purpose company concentrating on the casino gaming, hospitality, entertainment, and leisure time industries. Jericho entered into an agreement with Concrete Leveling Systems in March of 2017; Jericho became the gaming and hospitality division of Concrete Leveling Systems. Jericho acquired Vegas Winners, Inc. (VWI) in 2018. VWI provides sports gaming information, analysis, advice, and predictions using all available media and advertising formats.

Recently, Concrete Leveling Systems disclosed that its casino gaming and hospitality division, Jericho Associates, with its partners and associates entered into a formal binding Term Sheet with a California Tribe to design, build, and operate a new casino gaming and hotel resort on a major highway location. The complete Term Sheet designates this Partnership to be its Development Partner. It also gives it the right to a seven year management contract, earning a share of the net profits, or to be its slot machine vendor where the Partnership would provide all of the slot equipment and earn a share of the slot machine net profits. The expectation is that this project will be a “broadly-appealing” fully integrated resort and gaming destination with up to a 250,000 square foot gaming floor including 3,000 slot machines and 150 table games.

Jericho is in the pending stages of completing the terms of the March 24, 2017 performance agreement to finalize the acquisition of the publicly traded company (CLEV – OTC). Jericho has started the process of a corporate name change and new stock trading symbol to better reflect its core business of casino gaming, hospitality, and entertainment. It will seek to elevate its trading activities to either Nasdaq or NYSE.

Concrete Leveling Systems, Inc. (CLEV), closed Thursday's trading session at $2.40, up 54.8387%, on 3,007 volume with 18 trades. The average volume for the last 3 months is 773 and the stock's 52-week low/high is $0.007199999/$0.089900001.

Rhino Resource Partners LP (RHNO)

Zacks, MarketWatch, Mining Connection, GlobeNewswire, Annual Reports, TopPennyStockMovers, Marketbeat, Simply Wall St, 4-Traders, Dividend Channel, Wall Street Mover, and PCG Advisory reported earlier on Rhino Resource Partners LP (RHNO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Rhino Resource Partners LP is a diversified energy limited partnership. It concentrates on coal and energy related assets and activities. This includes energy infrastructure investments. Rhino is a diversified energy MLP (Master Limited Partnership). It produces coal in numerous basins in the U.S. Rhino Resource Partners has its head office in Lexington, Kentucky.

The Company, through acquisitions and other coal lease transactions, has substantially increased its proven and probable coal reserves and non-reserve coal deposits. Furthermore, Rhino has successfully increased its coal production by way of internal development projects.

   The Company produces metallurgical and steam coal in an array of basins across the U.S. as well as leases coal. Rhino’s strategy is to acquire coal reserves and properties with relatively long lives and that could undergo development with low risk at a reasonable cost.

Rhino produces steam coal used to produce electricity and metallurgical coal used in the steel-making process. In addition, the Company manages and leases coal properties and collects royalties from such management and leasing activities. Rhino also has oil and gas investments in the Cana Woodford region that provides added cash flows to its business. 

  In Central Appalachia, approximately 72 percent of its full-year 2019 thermal and met coal production has been contracted at increased prices in comparison to 2018. Rhino’s Pennyrile, Castle Valley and Hopedale operations are considerably sold out for 2019 at prices that are above the Company’s 2018 levels. Moreover, Rhino has executed long-term contracts with different utility customers for thermal coal for 2020 at Pennyrile and Castle Valley.

Rhino Resource Partners LP (RHNO), closed Thursday's trading session at $0.075, up 82.9268%, on 2,060 volume with 3 trades. The average volume for the last 3 months is 16,151 and the stock's 52-week low/high is $0.039999999/$1.00.

Provectus Biopharmaceuticals, Inc. (PVCT)

Top Stock Analysts,  Club Penny Stocks Network, The Street, Streetwise Reports, All Penny Stocks, Stock News Now, Wise Alerts, plrinvest, Investors Underground, Real Pennies, PennyStocks24, Top Penny Stock Movers, Street Insider, Street Authority Daily, and The Microcap News reported previously on Provectus Biopharmaceuticals, Inc. (PVCT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

OTCQB-listed, Provectus Biopharmaceuticals, Inc. is a clinical-stage oncology and dermatology Biopharmaceutical Company. It is developing new therapies for the treatment of solid tumor cancers and dermatologic diseases. The Company`s investigational oncology drug is PV-10.  PV-10 is an oncolytic immunotherapy enrolling patients in Phase 3 clinical trials for metastatic melanoma.  Provectus Biopharmaceuticals has its head office in Knoxville, Tennessee.

  PV-10 is an ablative immunotherapy under investigation in solid tumor cancers. PV-10 is a 10 percent solution of small molecule and halogenated xanthene Rose Bengal. It undergoes administration through direct injection into solid tumor cancers, including melanoma, liver, and breast. It is not designed to rely on a single pathway, receptor or antigen to work. There is no known resistance.

The intention of PV-10 is to kill only diseased cells upon injection into tumors. Provectus Biopharmaceuticals has received orphan drug designations from the Food and Drug Administration (FDA) for its melanoma and hepatocellular carcinoma indications. The Company completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

PH-10 is a topical investigational drug for dermatology and is a topical hydrogel formulation. It yields selective delivery of rose bengal disodium to epithelial tissues. Regarding PH-10 for psoriasis and atopic dermatitis, a mechanism of action study is underway to measure the clinical and cellular response to PH-10's active investigational agent. A total of 226 subjects have been treated with PH-10 in Phase 1 or Phase 2 Clinical Trials.

Provectus Biopharmaceuticals announced this past November that it was granted orphan drug designation (ODD) by the FDA for small molecule oncolytic immunotherapy PV-10 for the treatment of neuroblastoma. This is a non-Central Nervous System (CNS) pediatric solid tumor. Intratumoral injection of PV-10 can yield immunogenic cell death (ICD) in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells. ODD status was earlier granted to PV-10 for the treatments of metastatic melanoma in 2007 and hepatocellular carcinoma (HCC) in 2013.

Recently, Provectus Biopharmaceuticals announced that orphan drug designation (ODD) status was granted by the FDA to small molecule oncolytic immunotherapy PV-10 for the treatment of ocular melanoma (to include all melanoma disease affecting the eye and orbit). The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect less than 200,000 people in the United States. ODD status qualifies companies for certain benefits. These benefits include seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, as well as waiver of certain administrative fees.

Also recently, Provectus Biopharmaceuticals and the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) announced that OncoTargets and Therapy (OTT) published preclinical results from in vitro and animal tumor model studies on PV-10 for the treatment of neuroblastoma. POETIC is a group of 10 top-tier academic medical centers developing new pediatric cancer therapies.

The work was led by Dr. Aru Narendran and his team at the University of Calgary’s POETIC Preclinical and Drug Discovery Laboratory. Prior preclinical and clinical studies by other researchers have shown that intratumoral injection of PV-10 can yield immunogenic cell death in adult solid tumors and stimulate tumor-specific reactivity in circulating T cells.

According to the POETIC authors, “Our studies provide preclinical proof-of-concept data on the efficacy of PV-10 in neuroblastoma. Mechanistically, we have found that PV-10 acts by disrupting lysosomes, inducing cell cycle changes and initiating cell death by apoptosis. We have also identified several commonly used treatments with which PV-10 shows synergistic anti-tumor activity. Furthermore, we have validated the efficacy of PV-10 in vivo, using neuroblastoma xenograft mouse experiments.”

Provectus Biopharmaceuticals, Inc. (PVCT), closed Thursday's trading session at $0.097, up 35.4749%, on 1,105,293 volume with 94 trades. The average volume for the last 3 months is 378,278 and the stock's 52-week low/high is $0.215100005/$7.5999999.

RavenQuest BioMed, Inc. (RVVQF)

Stockwolf, OTC Markets, EconoTimes.com, TradingView, Dividend Investor, New Cannabis Ventures, Morningstar, Stockhouse, GlobeNewswire.com, Marketwatch, InvestorsHub, Marketfy, Barchart, Investopedia, Ceo.ca, Investing News Alerts, and Investors Hangout reported on RavenQuest BioMed, Inc. (RVVQF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A diversified publicly traded cannabis company, RavenQuest BioMed, Inc. is headquartered in Vancouver, British Columbia. It has divisions centered upon cannabis production, management services and consulting, and specialized research and development (R&D). Incorporated in 1987, the Company previously went by the name Ravencrest Resources, Inc. It changed its name to RavenQuest BioMed, Inc. in September of last year.

RavenQuest BioMed has announced that the OTC Markets Group advised the Company of its qualification and confirmed start of trading on the OTCQB market in the U.S, with immediate effect. RavenQuest’s common shares began trading under the symbol “RVVQF”.

The Company has a research partnership with McGill University (Montreal, Quebec). The work will be conducted via collaboration between two McGill laboratories. One is through Dr. Donald Smith – patented technologies for improvement of crop yields. The other is through Dr. Mark Ware – medical cannabis researcher; Director of clinical research at the Allen Edwards Pain Management Unit at the McGill University Health Center (MUHC).

RavenQuest BioMed’s Services Division delivers wide-ranging, integrated solutions to companies in the cannabis industry. The Company’s turnkey, end-to-end offering provides growing and drying technologies, patient and genetic management systems, as well as security management solutions.

Recently, RavenQuest BioMed announced it appointed Dr. Simerjeet Kaur, PhD, to lead Scientific Research & Development. She will lead RavenQuest’s R&D and scientific training efforts, specifically relating to the development of new high yielding, stress resistant Cannabis varieties for medicinal and recreational purposes. Dr. Kaur is an expert in plant breeding, genetics, plant physiology, as well as biochemistry.

RavenQuest BioMed has completed its Bloomera acquisition. It completed the acquisition of 8649081 Canada, Inc. (Bloomera), which is a Markham, Ontario headquartered licensed producer of cannabis under the Access to Cannabis for Medical Purposes Regulations.

With this transaction, RavenQuest BioMed acquired all of the outstanding share capital of Bloomera in consideration for a cash payment of $15,000,000, and the issuance of 10,400,000 common shares to the existing shareholders of Bloomera.

At present, Bloomera holds a Health Canada License to Cultivate and will initially add roughly 2,000 kilograms of annual production of cannabis to RavenQuest’s investment division.

RavenQuest BioMed has also announced that it signed a Memorandum of Understanding (MOU) with Fort McMurray #468 First Nation (FM 468) to collaborate in the development, operation, and also financing of a purpose-built facility for the production of cannabis on lands controlled by FM 468.

RavenQuest has developed an indigenous-focused, end-to-end solution for cannabis production and sale on sovereign land. It will provide its expertise to deliver the technical knowledge, staff resources, and financing opportunities as they relate to the development of the Production Facility, initially sized at 24,000 square feet. In consideration, RavenQuest will receive a 30 percent ownership interest in such a facility.

RavenQuest BioMed, Inc. (RVVQF), closed Thursday's trading session at $0.0079, up 31.6667%, on 44,719 volume with 9 trades. The average volume for the last 3 months is 100,132 and the stock's 52-week low/high is $0.001/$0.049499999.

Kush Bottles, Inc. (KSHB)

Stock News Now, The Street,  StreetAuthority Daily, CFN Media Group, Promotion Stock Secrets, and SmallCapVoice reported  on Kush Bottles, Inc. (KSHB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Kush Bottles, Inc. is a sales and distribution platform that offers packaging, supplies, vaporizers, accessories, and branding solutions for the regulated cannabis industry. The Company provides certified child-resistant and custom-branded solutions in all States that permit medical or recreational cannabis use. Kush Bottles is the only marijuana packaging company with numerous full-service facilities across the United States. The Company has its headquarters and California fulfillment center in Santa Ana, California.

Kush Bottles acquired CMP Wellness, LLC  (Los Angeles, California) last year. CMP is a privately held distributor of vaporizers, cartridges, and accessories.  The Company also acquired the web domain Roll-uh-Bowl.com. This is an online distribution platform for retail sales of collapsible and unbreakable medical-grade silicone water pipes.

Kush Bottles provides pop top bottles; child resistant exit, paper exit, and foil barrier bags; tubes; and polystyrene, polypropylene, or silicone containers to urban farmers, greenhouse growers, and medical and recreational cannabis dispensaries. The Company concentrates on providing the highest quality medical and food grade packaging.  In addition, Kush Bottles concentrates on choosing products that are environmentally friendly and manufactured within the United States.  

Kush Bottles now regularly services more than 4,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. In addition, the Company has opened a new Product Development and Genomics Lab in San Diego, California to produce unique terpene formulations.

  Kush Bottles has launched the marijuana industry's first online system. The system enables customers to design custom-branded packaging solutions. The tool makes it easier for customers to place orders. The expectation is that this will lead to a higher conversion rate and a better Return on Investment  (ROI). 

  Kush Bottles has launched a Food and Drug Administration (FDA) compliant Kush Canister™ to safely and securely store cannabis products for resale purposes. The canister can fit just over one ounce of cannabis flower. The canister has a certified child resistant push-top to comply with regulations in the States that require child resistant packaging.

Kush Bottles has announced it was chosen by Future Farm Technologies, Inc. (FFRMF) to develop a set of customized packaging and comprehensive compliance solutions to support its expansion into new territories. Kush Bottles will support Future Farm's expansion. It will also provide branded packaging solutions to ensure Future Farm maintains compliance with State-level regulations at all times.

Future Farm is promptly expanding its footprint in the cannabis and hemp sectors across the nation. Its emphasis is on California, Massachusetts, Maine, Florida and Puerto Rico.

Kush Bottles has also announced that it entered into a strategic partnership with a top cannabis ancillary fund, Merida Capital Partners. Kush has received a $6 million equity investment from Merida to speed up its near and long-term growth strategy. Kush Bottles’ plan is to use the proceeds to expand its product portfolio, build new distribution channels and penetrate new legalized markets.

Kush Bottles, Inc. (KSHB), closed Thursday's trading session at $0.555, up 28.4425%, on 1,385,179 volume with 810 trades. The average volume for the last 3 months is 537,453 and the stock's 52-week low/high is $0.0171/$0.125200003.

Stealth Technologies, Inc. (STTH)

NetworkNewsWire and RedChip reported previously on Stealth Technologies, Inc. (STTH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Stealth Technologies, Inc. is a technology business listed on the OTC Markets Group’s OTCQB. The Company previously went by the name Excelsis Investments, Inc. It changed its name to Stealth Technologies, Inc. in July 2016. Stealth Technologies engages in identifying and capitalizing on technology and associated markets. The Company produces products for personal and financial protection.

Incorporated in 2010, Stealth Technologies has its corporate office in Largo, Florida. It became public through a reverse merger in 2012.

Moreover, Stealth Technologies announced in March of this year the completion of five new products. Currently, these products are staged in a large direct response retailer's quality assurance and legal department. They are under final review to ensure that marketing claims associated with each product are accurate when measured against actual performance levels of each product, and that assurance and inventory is satisfactory and has met all quality control factors. Stealth Technologies’ strategic initiative is to expand its product footprint across varied industries and distributors.

The Company has developed a group of products to protect against "electronic pickpockets," emergency response latency, credit fraud protection, and cell phone data protection. Its initial product to market is the Stealth Card.

The design of the Stealth Card is to protect the Radio-Frequency Identification (RFID) chip in a consumer's credit card from electronic stealing or pickpocketing, which uses a smartphone, credit card reader, or RFID antenna to remotely access data stored on the consumer's Smartchip. Stealth Card renders the chipped information invisible to intrusion.

The Stealth Card is a 100 percent USA product. The Stealth Card is manufactured from Stealth Technologies’ laboratory and research/development facility in West Virginia to its manufacturing facility in Massachusetts.

Development for the Stealth Card started in 2012. This is when Company Founder and Chief Executive Officer (CEO), President, and Director, Mr. Brian McFadden, observed the worldwide shift towards smart chip card technology to transmit and process credit card/debit card transactions. With Europe and Asia already making the transition away from the magnetic strip to smart chip cards, Mr. McFadden believed the United States market would need to follow suit.

To use the Stealth Card, a person places a Stealth Card in their wallet, pocket, change purse or anywhere they carry their credit cards. One card can protect up to 12 cards in a wallet. The card can be physically placed anywhere in a wallet or pocket.

The card does not need to be in the front or back of one’s wallet. The Stealth Card provides effective protection irrespective of where it’s placed in relation to one’s credit cards.

In December 2016, Stealth Technologies announced the development of the 911 Help Now Generation II Product. The 911 Help Now product provides a direct two-way voice connection to emergency service providers. The 911 Help Now pendent works by pressing the Help Now button and then a person is connected.

Stealth Technologies has a number of other products under development. The Company is exploring potential military applications of its proprietary technologies.

Along with the Stealth Card and the 911 Help Now Generation II Product, Stealth Technologies’ portfolio includes Data Secure Plus, which is new to market. Its portfolio also includes Stealth Mobile.

Stealth Technologies, Inc. (STTH), closed Thursday's trading session at $0.0142, up 35.2381%, on 110,050 volume with 7 trades. The average volume for the last 3 months is 163,233 and the stock's 52-week low/high is $0.010999999/$1.00.

The QualityStocks Company Corner

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Mullen Technologies, an emerging electric vehicle (“EV”) manufacturer and technology company that previously announced a definitive agreement to merge with Net Element (NASDAQ: NETE) in a stock-for-stock reverse merger, this morning announced that it will commence the build-out of its pilot manufacturing facility and begin taking pre-orders of its MX-05 fully electric SUV starting on October 1st, 2020. To view the full press release, visit http://ibn.fm/UV1gJ

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Thursday's trading session at $8.60, up 32.9212%, on 39,863,297 volume with 228,550 trades. The average volume for the last 3 months is 849,203 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

These days, critics of the U.S. health-care system may be tempering their censure. After all, the sector has proved its worth in the battle against the coronavirus pandemic. Yet some of the fault-finding had merit. The system is bloated and plagued by inefficiencies. Even doctors agree, as a recent report in the “Journal of the American Medical Association” (“JAMA”) indicates (http://nnw.fm/hPid6). Digital technologies may help streamline processes and methodologies, making some areas, such as pharmaceutical distribution, more efficient and, importantly, more effective. With that in mind, the Trxade Group (NASDAQ: MEDS) has developed a pharmaceutical supply-chain trading platform that is already helping pharmacies cut costs and get faster delivery.

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Thursday's trading session at $5.05, up 1.2024%, on 17,095 volume with 284 trades. The average volume for the last 3 months is 50,948 and the stock's 52-week low/high is $3.00/$3.77010011.

Recent News

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

As “stewards of the environment”, Sustainable Green Team (OTC: SGTM) takes its role in environmental remediation seriously by providing beneficial solutions for tree and storm waste disposal. In the wake of Hurricane Laura, SGTM rose to the occasion by securing a contract for ArborPro of Mississippi Inc. (APM), one of its strategic partners. The recovery work planned will kickstart SGTM’s process, diverting many destroyed trees from landfills to the company’s processing facilities that will transform them into environmentally beneficial organic products.

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Thursday's trading session at $1.50, up 15.3846%, on 355 volume with 3 trades. The stock's 52-week low/high is $1.04999995/$3.35739994.

Recent News

Kaival Brands Innovations Group Inc. (OTCQB: KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (OTCQB: KAVL).

Kaival Brands (OTCQB: KAVL), a company focused on developing products into mature, dominant brands, recently entered into a partnership with Bidi Vapor LLC. Under the partnership, Kaival Brands has exclusive global distribution rights for the Bidi(TM) Stick, an innovative product made from high-quality components and equipped with a long-lasting battery and class A nicotine. The move has already had a positive impact on Kaival Brands, assisting the company with expedited growth. To view the full article, visit: https://nnw.fm/05qfo

Kaival Brands Innovations Group Inc. (OTCQB: KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (OTCQB: KAVL), closed Thursday's trading session at $0.38, up 4.2524%, on 74,787 volume with 31 trades. The average volume for the last 3 months is 184,860 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE: American: UUUU) (TSX: EFR) was featured today in a publication from MiningNewsWire, examining how, in the tiny isle of Minami-tori-shima, scientists have discovered a huge deposit of rare earth elements. The lode is not physically located on the island but in the clay sediment in the south of the seamount that the island sits on. The super deposits are bits of fish scales, teeth and bones that form the element traps.Scientists from Japan have calculated that the clay, which covers a 2500 km2 zone in the south of the island, can supply four of the earth’s rare elements’ requirements for hundreds of years.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Thursday's trading session at $1.55, even for the day, on 1,162,366 volume with 3,037 trades. The average volume for the last 3 months is 1,582,700 and the stock's 52-week low/high is $0.810000002/$6.25.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF).

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) announces the availability of a broadcast titled, “One of ‘World’s Best-Performing Mainstream Assets,’ Gold Heading for Record Highs.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast. To view the full editorial, please visit: https://www.nnw.fm/b2non.

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: ATUMF), closed Thursday's trading session at $0.27, even for the day, on 38,812 volume with 6 trades. The stock's 52-week low/high is $0.27/$0.2932.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”) for planned Berubicin clinical trials. IAG, a leading medical imaging group, and CNS will work together to provide critical imaging services and imaging data analysis for the trials. IAG has an extensive background of partnering with oncology companies to deliver centralized readings and analysis of patient responses in real time. IAG’s expertise will allow CNS to review efficacy assessments and explore the advanced-treatment manifestations. To view the full press release, visit http://ibn.fm/EQvO3. Also today, the company was featured in a publication from BioMedWire, examining how a team of scientists from the Institute for Molecular and Clinical Ophthalmology Basel (“IOB”) that was led by Botond Roska, in collaboration with the Novartis Institutes for BioMedical Research, have created indistinguishable replicas of human retinas in culture. These will be used to help find the specific cell types that are affected by genetic eye ailments. This project, which took 6 years, will significantly speed up the process of developing new therapies for eye ailments.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $1.76, off by 2.2222%, on 50,481 volume with 239 trades. The average volume for the last 3 months is 106,910 and the stock's 52-week low/high is $1.258/$5.69.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) today announces its placement in an editorial published by Network NewsWire ("NNW"), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.To view the full publication, “New Opportunities Abound for Specialty Beverage, Water Companies,” please visit: https://nnw.fm/5nMwH. Also today, the company was featured in the 420 with CNW by CannabisNewsWire.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Thursday's trading session at $1.21, off by 1.626%, on 1,211,145 volume with 3,720 trades. The average volume for the last 3 months is 1,560,996 and the stock's 52-week low/high is $0.40/$2.60.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies. Also today, the company was featured in a publication from BioMedWire, examining how, since the coronavirus crisis was declared a pandemic, N95 masks, which are a design of personal protective equipment have been in short supply.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $0.9376, off by 4.9666%, on 4,380,649 volume with 9,377 trades. The average volume for the last 3 months is 1,411,403 and the stock's 52-week low/high is $0.006/$1.09000003.

Recent News

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire Corp. (OTC: SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

  • Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
  • Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
  • The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

  • Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
  • Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
  • Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Thursday's trading session at $0.0149, off by 14.3678%, on 280,565 volume with 16 trades. The average volume for the last 3 months is 1,085,937 and the stock's 52-week low/high is $0.109999999/$0.446000009.

Recent News

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)

The QualityStocks Daily Newsletter would like to spotlight Exro Technologies Inc. (OTCQB: EXROF).

Exro Technologies Inc. (TSXV:EXRO)(OTCQB:EXROF) (the "Company"), a leading technology company which has developed a new class of power electronics for electric motors and powertrains, is pleased to announce it has initiated a collaboration with Heinzmann GMBH & Co. KG ("Heinzmann") to integrate Exro's patented coil drive technology into micro mobility applications.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian technology company, is an innovative pioneer in the energy sector. Exro has developed and commercialized an electric power module (EPM) that integrates into existing motor systems to make them smarter. Exro’s patented technology optimizes existing motor performance by automatically sensing and adapting operating parameters to an optimized state, creating measurable efficiency gains, reduced mechanical components and increased system availability.

Applications

Exro’s technology and efficiency optimization algorithms improve the performance and efficiency of electric motors by manipulating power delivery to individual coils, thereby enabling the ability to expand operating parameters. This novel approach is scalable and can be utilized in most variable torque applications.

The widespread applications of Exro’s technology apply to optimizing the performance of electric vehicles, locomotive traction applications, industrial motors, and other variable torque applications that benefit from smart energy conversion.

Intellectual Property

Exro’s proprietary, patented software controls electric motor coils through individual coil switching. This introduction of intelligence into energy conversion at the level of individual coils results in expanded speed/torque capability, improved machine efficiency, reliability, safety and maintenance across a wider operating range. Exro’s advanced control algorithms create smart, real-time optimized power management.

Exro currently holds 15 patents, with 8 patents pending and additional patents under development. The company continues to expand its IP portfolio to support its goal of becoming a globally recognized leader in leveraging advanced control algorithms to improve the performance, efficiency and longevity of electric motors and generators.

Market Opportunity

Electric motors are the single biggest consumer of electricity. They account for about two-thirds of industrial power consumption and about 45% of global power consumption, according to an analysis by the International Energy Agency. Exro’s technology seeks to give industries a new way to look at energy—from electric vehicles, to industrial equipment, to renewable applications like wind farms; we are improving the way energy is consumed.

Laboratory Expansion

The 6,500-square-foot Exro Innovation Center (EIC), scheduled to open spring of 2020 in Calgary, will transition the current Victoria lab into one Calgary based center. The company’s new laboratory space will expand its service capabilities to customers, provide larger test capabilities, and showcase how Exro’s technology can be applied to dramatically improve the performance of electrical motors.

The EIC will also host collaborative events to explore advances in energy consumption and electric motor innovations, with participants from across Canada and around the world.

Strategic Partnerships

  • A strategic agreement with Finland’s Aurora Powertrains Oy, which in 2019 released an all-electric production snowmobile called the “eSled,” will see Exro’s technology added to the Aurora electric powertrain. The snowmobile sector’s economic footprint is estimated at $26 billion in the U.S., $8 billion in Canada, and $5 billion in Europe and Asia.
  • An agreement with Potencia in Mexico serving the last mile vehicle segment will integrate Exro’s custom drive and EPM module into small passenger commercial vehicles (taxis) and fleet delivery trucks
  • A licensing agreement with Motorino Electric, a leader in the Canadian electric transportation industry, will integrate Exro’s Electric Power Module technology into Motorino’s CTi electric bicycle.

Management

Chief Executive Officer Sue Ozdemir is a proven leader in the innovation and manufacturing of electric motors. She has nine years of accomplishments at General Electric, acting as CCO and the CEO of GE’s Small Industrial Motors Division, overseeing the division’s North American and international markets – ultimately building the division into a $160 million enterprise.

Chief Commercial Officer Josh Sobil is leading the seamless adoption of Exro’s growing product portfolio focused on the mobility segment and opening doors in all segments including agriculture, heavy industry, energy, construction, among others.

Executive Chairman Mark Godsy is a serial technology entrepreneur who has been involved in many top tier ventures, including two of Canada’s most successful biotech companies.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), closed Thursday's trading session at $1.04, up 13.0435%, on 650,758 volume with 509 trades. The average volume for the last 3 months is 350,107 and the stock's 52-week low/high is $4.54500007/$9.22999954.

Recent News

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company, Inc. ("Supreme Cannabis" or the "Company") (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced its financial and operating results for the three and twelve months ended June 30, 2020. Supreme Cannabis' Management Discussion & Analysis ("MD&A") and consolidated financial statements ("Financial Statements") for the year and fourth quarter ended June 30, 2020 ("Q4 2020"), along with all previous public filings of The Supreme Cannabis Company, Inc., may be found on SEDAR at www.SEDAR.com . All figures are in Canadian dollars.

Supreme Cannabis Company Inc. (TSX: FIRE) (OTC: SPRWF) is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees and culture of innovation. The company aims to grow the world’s best legal cannabis and become a leader in the global industry. Supreme Cannabis calls its Toronto Venture Exchange stock symbol, “FIRE,” a testament to the company’s passion for cannabis and obsession with quality.

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as one of Canada’s most premium cannabis producers, the company sees itself at the center of this global shift.

A key piece of Supreme Cannabis’ ability to fulfill its mission is its flagship brand, 7ACRES, a wholly owned subsidiary that operates a 440,000-square-foot hybrid cultivation facility in Kincardine, Ontario. 7ACRES is focused on building a core competency in scaled high-quality cannabis production. With a best-in-class cultivation facility producing a competitive product that fuels a leading premium brand, Supreme Cannabis has achieved a differentiated advantage in cultivation IP, products and branding. The company’s foundational investment in premium cultivation has secured it a leadership position in the industry as the Canadian market becomes more competitive and matures.

Since legalization, 7ACRES has brought five premium flower strains to market in Canada. The demand for 7ACRES product continues with the company’s most recent launch of Jack Haze, a new proprietary premium cultivar. The company’s first sativa-dominant strain, Jack Haze offers rare sensory characteristics, delivering high THC content with a terpinolene forward profile, including a complex aroma with notes of citrus, pine and warm spice. As it develops its next winning strain, 7ACRES continues to prioritize subjective quality. In the Canadian cannabis market, this approach has established 7ACRES as a well-known premium brand that commands premium pricing coast-to-coast.

In addition to 7ACRES, Supreme Cannabis has built a diversified portfolio of focused consumer-driven brands:

  • Sugarleaf by 7AC – this new brand widens Supreme Cannabis’ product offerings and targets consumers who are looking for more refined, milder consumption experience as they discover their own cannabis taste preferences and desires. Product formats under this brand are focused on offering consumers elegant and convenient cannabis experiences.
  • Blissco — dedicated to providing wellness focused consumers with premium cannabis products, education, and outstanding customer care. Blissco is focused on bringing its collection of premium whole-flower CBD oils to market.
  • Truverra — focused on being a global leader in the development, production and marketing of hemp and cannabis-derived medicinal products with clinically proven efficacy. With over 25 SKUs sold online in the UK and Europe, Truverra is ideally positioned to address emerging international cannabis opportunities.
  • Khalifa Kush Enterprises — formed through a prestigious international partnership with Khalifa Kush Enterprises (KKE) Canada, the Canadian counterpart to the popular U.S. cannabis brand KKE formed by Wiz Khalifa. Together, Supreme Cannabis and KKE Canada are developing and launching a lineup of premium cannabis products, including a future line based on the well-known Khalifa Kush strain.

Each of Supreme Cannabs’ brands and partnerships have been strategically identified and designed to support the company’s mission to enhance the lives of consumers through positive cannabis experiences. Equally important to delivering desirable consumer experiences is the infrastructure supporting the company’s brands and products. From seed to sale, supreme cannabis continues to build an impressive group of operating assets that serve key functions throughout the value chain:

  • Cultivation – for starters, there is Supreme Cannabis’ foundational flagship asset, its 440,000-square-foot cultivation facility in Kincardine, Ontario. With over 600 employees, 24 grow rooms, and best-in-class processing equipment and procedures, this facility is expected to reach an annual production capacity of 50,000 kilograms in the near-term. In this purpose-built facility, the company grows small-batch high-quality cannabis from 10,000-square-foot grow rooms and completes a proprietary hang-dry for up to two weeks.
  • Extraction – with the acquisition of Blissco in fiscal 2019, in addition to the Blissco wellness brand, Supreme Cannabis gained a 12,000-square-foot dedicated extraction facility in Langley, BC. This facility conducts both C02 and ethanol extraction and with the recent receipt of its oil sales license from Health Canada, it now produces Blissco branded CBD oils and expects to fill vaporizer pods for a partnership between the company’s 7ACRES brand and Pax Labs.
  • Manufacturing – most recently, the company announced its 107,000-square-foot processing, packaging and manufacturing facility in Kitchener, naming the facility Supreme Cannabis Kitchener. In Q4 FY2020, the company expects to begin whole flower packaging and pre-roll manufacturing for Supreme Cannabis brands at the Kitchener Facility. In the long-term, in additional to processing its own inputs, Supreme Cannabis intends generate incremental revenue by packaging, distributing and branding third-party cannabis inputs from quality-focused cultivators.
  • R&D and Product Testing – In Q1 FY2020, Supreme Cannabis closed the acquisition of Truverra and acquired a 5,000-square-foot facility licensed under Canadian Clinical Cannabinoids Inc. in Scarborough, Ontario (“Supreme Cannabis Scarborough”). Supreme Cannabis Scarborough provides R&D space for the company to test new products and develop medicinal science intellectual property. In the near-term, with the legalization of 2.0 cannabis products, this centre for innovation will be testing and bringing concentrate products to market under the 7ACRES brand.

Supreme is committed to continue to identify new opportunities to grow and strengthen its impressive portfolio of operating assets and brands and scale its strong Canadian business globally.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Thursday's trading session at $0.1088, up 1.3035%, on 411,676 volume with 120 trades. The average volume for the last 3 months is 561,989 and the stock's 52-week low/high is $0.079300001/$0.248799994.

Recent News

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (the " Company ") (TSX: RIV) (OTC: CNPOF) announced the voting results of its annual general and special meeting of shareholders (the " Meeting ") held today. In total, 59,090,152 of the Company's issued and outstanding subordinated voting shares (each carrying one vote per share) and 36,468,318 of the Company's issued and outstanding multiple voting shares (each carrying 20 votes per share), representing 89.104% of the votes attached to all outstanding shares of the Company, were represented in person or by proxy at the Meeting.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Thursday's trading session at $0.53, off by 0.581504%, on 10,312 volume with 22 trades. The average volume for the last 3 months is 59,340 and the stock's 52-week low/high is $0.630800008/$3.71000003.

Recent News

Cannabis Global Inc. (CBGL)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Global, Inc. (CBGL).

Cannabis Global (OTC: CBGL), a cannabinoid and hemp-extract, science-forward company developing infusion and delivery technologies, has entered into a three-year distribution agreement with Baja United Group. The three-year agreement covers nationwide distribution of CBGL’s Hemp You Can Feel(TM) branded products, including the newest addition to that product line, Hemp You Can Feel hemp-based alcohol substitute cocktail mixers. To view the full press release, visit http://cnw.fm/PbanG

Cannabis Global Inc. (CBGL) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June 2019 and announced its intent to enter the cannabis sector. In August 2020, it changed its corporate identity from MCTC Holdings Inc. to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, CBGL plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

CBGL is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. CBGL believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

CBGL leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, CBGL has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

CBGL has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

CBGL collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market CBGL’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by CBGL. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

CBGL CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

CBGL founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at Cannabis Global.

Cannabis Global, Inc. (CBGL), closed Thursday's trading session at $0.0915, off by 8.9099%, on 72,538 volume with 29 trades. The stock's 52-week low/high is $0.150000005/$2.05999994.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.